Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

Part A--medical results.

James Adams, Matthew Baral, Elizabeth Geis, Jessica Mitchell, Julie Ingram, Andrea Hensley, Irene Zappia, Sanford Newmark, Eva Gehn, Robert A. Rubin, Ken Mitchell, Jeff Bradstreet, Jane El-Dahr

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. METHODS: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. RESULTS: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. CONCLUSION: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.

Original languageEnglish (US)
Pages (from-to)16
Number of pages1
JournalBMC Clinical Pharmacology
Volume9
StatePublished - 2009

Fingerprint

Succinic Acid
Safety
Poisons
Glutathione
Metals
Platelet Count
Therapeutics
Antimony
Bismuth
Tungsten
Tin
Thallium
Chromium
Mercury
Minerals
Autism Spectrum Disorder
Potassium
Blood Platelets
Placebos
Inflammation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Adams, J., Baral, M., Geis, E., Mitchell, J., Ingram, J., Hensley, A., ... El-Dahr, J. (2009). Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results. BMC Clinical Pharmacology, 9, 16.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : Part A--medical results. / Adams, James; Baral, Matthew; Geis, Elizabeth; Mitchell, Jessica; Ingram, Julie; Hensley, Andrea; Zappia, Irene; Newmark, Sanford; Gehn, Eva; Rubin, Robert A.; Mitchell, Ken; Bradstreet, Jeff; El-Dahr, Jane.

In: BMC Clinical Pharmacology, Vol. 9, 2009, p. 16.

Research output: Contribution to journalArticle

Adams, J, Baral, M, Geis, E, Mitchell, J, Ingram, J, Hensley, A, Zappia, I, Newmark, S, Gehn, E, Rubin, RA, Mitchell, K, Bradstreet, J & El-Dahr, J 2009, 'Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.', BMC Clinical Pharmacology, vol. 9, pp. 16.
Adams, James ; Baral, Matthew ; Geis, Elizabeth ; Mitchell, Jessica ; Ingram, Julie ; Hensley, Andrea ; Zappia, Irene ; Newmark, Sanford ; Gehn, Eva ; Rubin, Robert A. ; Mitchell, Ken ; Bradstreet, Jeff ; El-Dahr, Jane. / Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : Part A--medical results. In: BMC Clinical Pharmacology. 2009 ; Vol. 9. pp. 16.
@article{ef86ee4620684e778a8d7fe427ded09c,
title = "Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.",
abstract = "BACKGROUND: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. METHODS: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. RESULTS: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. CONCLUSION: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.",
author = "James Adams and Matthew Baral and Elizabeth Geis and Jessica Mitchell and Julie Ingram and Andrea Hensley and Irene Zappia and Sanford Newmark and Eva Gehn and Rubin, {Robert A.} and Ken Mitchell and Jeff Bradstreet and Jane El-Dahr",
year = "2009",
language = "English (US)",
volume = "9",
pages = "16",
journal = "BMC Clinical Pharmacology",
issn = "1472-6904",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

T2 - Part A--medical results.

AU - Adams, James

AU - Baral, Matthew

AU - Geis, Elizabeth

AU - Mitchell, Jessica

AU - Ingram, Julie

AU - Hensley, Andrea

AU - Zappia, Irene

AU - Newmark, Sanford

AU - Gehn, Eva

AU - Rubin, Robert A.

AU - Mitchell, Ken

AU - Bradstreet, Jeff

AU - El-Dahr, Jane

PY - 2009

Y1 - 2009

N2 - BACKGROUND: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. METHODS: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. RESULTS: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. CONCLUSION: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.

AB - BACKGROUND: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. METHODS: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. RESULTS: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. CONCLUSION: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.

UR - http://www.scopus.com/inward/record.url?scp=70450261738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450261738&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 16

JO - BMC Clinical Pharmacology

JF - BMC Clinical Pharmacology

SN - 1472-6904

ER -